Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Greater Access - The More the Merrier

This article was originally published in RPM Report

Executive Summary

The 47 million uninsured Americans are a cause célèbre for politicians seeking to prove that the US health care system is broken. Senators Barack Obama and John McCain look upon this huge number as a national embarrassment and vow in their health care platforms to expand access aggressively.

You may also be interested in...



Health Care Reform and the Changing Dynamics Between Payers and Drug Makers

Why drug makers should pay close attention to the pressures bearing down on payers.

Medicare Price Negotiation -- Waiting for the Other Shoe to Drop

At present, the federal government is prohibited from negotiating outpatient prescription drug prices with pharmaceutical companies on behalf of Medicare Part D. But, Senator Barack Obama (and perhaps John McCain, whose stance on this policy is unclear) favors a health system in which the government can bring its bargaining power to the table. What happens when the other shoe drops?

Health Care and the 2008 Election: Revolution, Reform or Return to Business-as-Usual?

As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel